In:
European Journal of Haematology, Wiley, Vol. 94, No. 6 ( 2015-06), p. 554-557
Abstract:
Brentuximab Vedotin is an antibody – drug conjugate targeting CD 30. We report a case of severe cytokine release syndrome ( CRS ) after administration of the first dose of Brentuximab Vedotin in a 64‐yr‐old patient with relapsed systemic anaplastic large cell lymphoma (s ALCL ). To our knowledge, this is the first case of CRS to B rentuximab Vedotin described in the literature. However, CRS to Brentuximab Vedotin might be underestimated, as the drug has not been tested in large phase III trials yet.
Type of Medium:
Online Resource
ISSN:
0902-4441
,
1600-0609
DOI:
10.1111/ejh.2015.94.issue-6
Language:
English
Publisher:
Wiley
Publication Date:
2015
detail.hit.zdb_id:
2027114-1